

RECEIVED
CENTRAL FAX CENTER
DEC 22 2006

Attorney Docket No. 5515.214-US
Serial No. 09/886,311
Filed: June 21, 2001
Inventors: Knudsen et al.
Via Facsimile No.: 571-273-8300

Amendments To The Claims

The listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing Of Claims:

Claims 1-91 (Cancelled)

Claim 92 (Currently Amended) A derivative ~~of an analogue~~ of exendin-4 or a fragment thereof, ~~where said analogue has an amino acid sequence that differs from the amino acid sequence of exendin-4 by the substitution of up to ten amino acid residues with any α -amino acid residue, and~~ wherein said derivative has one lipophilic substituent attached, optionally via a spacer, to an amino acid residue of said ~~analogue~~ exendin-4 or fragment thereof, which is not the N-terminal or C-terminal amino acid residue of said ~~analogue~~ exendin-4 or fragment thereof.

Claims 93-95 (Cancelled)

Claim 96 (Previously Presented) The derivative of claim 92, wherein the lipophilic substituent has 4 to 40 carbon atoms.

Claim 97 (Previously Presented) The derivative of claim 96, wherein the lipophilic substituent has 8 to 25 carbon atoms.

Claim 98 (Previously Presented) The derivative of claim 96, wherein the lipophilic substituent is attached by means of a spacer.

Claim 99 (Previously Presented) The derivative of claim 98, wherein the spacer is an unbranched alkane α,ω -dicarboxylic acid group having from 1 to 7 methylene groups.

Attorney Docket No. 5515.214-US
Serial No. 09/886,311
Filed: June 21, 2001
Inventors: Knudsen et al.
Via Facsimile No.: 571-273-8300

Claims 100-103 (Cancelled)

Claim 104 (Previously Presented) The derivative of claim 96, wherein the lipophilic substituent is a straight-chain or branched acyl group.

Claim 105 (Previously Presented) The derivative of claim 104, wherein the acyl group is of the formula $\text{CH}_3(\text{CH}_2)_n\text{CO}-$, wherein n is 4 to 38.

Claim 106 (Previously Presented) The derivative of claim 105, wherein the acyl group is $\text{CH}_3(\text{CH}_2)_6\text{CO}-$, $\text{CH}_3(\text{CH}_2)_8\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{10}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{12}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{14}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{16}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{18}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{20}\text{CO}-$ or $\text{CH}_3(\text{CH}_2)_{22}\text{CO}-$.

Claims 107-121 (Cancelled)

Claim 122 (Previously Presented) A pharmaceutical composition comprising a derivative of claim 92 and a pharmaceutically acceptable vehicle or carrier.

Claim 123 (Previously Presented) A method of treating insulin dependent or non-insulin dependent diabetes mellitus in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a derivative of claim 92 and a pharmaceutically acceptable carrier.

Claims 124-135 (Cancelled)